Blastic Plasmacytoid Dendritic Cell Neoplasm clinical trials

Explore recruiting blastic plasmacytoid dendritic cell neoplasm clinical trials.

Recruiting blastic plasmacytoid dendritic cell neoplasm studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Blastic Plasmacytoid Dendritic Cell Neoplasm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

TAGVEN "Open label phase II study evaluating the efficacy and safety of the combination of tagraxofusp and venetoclax in treatment-naive blastic plasmacytoid dendritic cell neoplasm patients"

France

Therapeutic exploratory (Phase II) EU CTIS Study details

An open-label, first-in-human, dose-escalation/expansion study of SAR443579 administered as single agent by intravenous infusion in adult and pediatric participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)

France, Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

CAR123 T cell treatment of relapsed/refractory hematologic malignancies.

Czechia

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Blastic Plasmacytoid Dendritic Cell Neoplasm trials by city

Blastic Plasmacytoid Dendritic Cell Neoplasm in Toronto Blastic Plasmacytoid Dendritic Cell Neoplasm in Vancouver Blastic Plasmacytoid Dendritic Cell Neoplasm in Montreal Blastic Plasmacytoid Dendritic Cell Neoplasm in Calgary Blastic Plasmacytoid Dendritic Cell Neoplasm in Edmonton Blastic Plasmacytoid Dendritic Cell Neoplasm in Ottawa Blastic Plasmacytoid Dendritic Cell Neoplasm in Winnipeg Blastic Plasmacytoid Dendritic Cell Neoplasm in Quebec City Blastic Plasmacytoid Dendritic Cell Neoplasm in Hamilton Blastic Plasmacytoid Dendritic Cell Neoplasm in Kitchener Blastic Plasmacytoid Dendritic Cell Neoplasm in London Blastic Plasmacytoid Dendritic Cell Neoplasm in Halifax Blastic Plasmacytoid Dendritic Cell Neoplasm in New York Blastic Plasmacytoid Dendritic Cell Neoplasm in Los Angeles Blastic Plasmacytoid Dendritic Cell Neoplasm in Chicago Blastic Plasmacytoid Dendritic Cell Neoplasm in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease